ArticleNature2018
Prediction of acute myeloid leukaemia risk in healthy individuals.
Abstract read
In one paragraph
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 508 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
508citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
508 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis.Blood advances · 2024Pooled it
- Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML.Blood advances · 2024Trial
- Inflammation as a central driver in AML pathogenesis and therapy resistance.Science China. Life sciences · 2026Review
- Clinical Impact and Dynamics of Clonal Hematopoiesis withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression.Blood · 2026Article
- Derivation of a blood count-based machine learning model to prioritise sequencing for high-risk clonal haematopoiesis: a retrospective cohort study.EClinicalMedicine · 2026Article
- Prefibrotic bone marrow microenvironment is a hallmark of clonal hematopoiesis.Nature immunology · 2026Article
- ELN vs. IPSS-M in MDS/AML: Which Prognostic System Should Guide Clinical Decision-Making?Cancers · 2026Review
- Clinical management of clonal hematopoiesis.Cancer · 2026Review
- A single-cell lens into the co-evolution of genotypes and phenotypes in cancer.Nature reviews. Cancer · 2026Review
- Are there missed warning signals before traffic-related traumatic spinal cord injury? An exploratory case-control study using electronic health records.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2026Article
- Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.Leukemia · 2026Review
- Landscape of Somatic Mutations in a Large Cohort of Chinese Patients With Immune Dysregulations.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Article
- Article
- Mosaic chromosomal alterations are suppressed in older adults with HIV.Communications biology · 2026Article
- The blood remembers: HSC-iM and the cancer continuum.Blood cancer journal · 2026Article
- Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.The Journal of clinical investigation · 2026Article
- Article
- Clonal hematopoiesis of indeterminate potential (CHIP)-a pivotal contributor of aging and related disorders.Annals of translational medicine · 2026Review
448 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
75 authors.
Sagi AbelsonPrincess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.
Grace CollordWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Stanley W K NgInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
Omer WeissbrodDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel.
Netta Mendelson CohenDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel.
Elisabeth NiemeyerDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Noam BardaClalit Research Institute, Tel Aviv, Israel.
Philip C ZuzarteOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Lawrence HeislerOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Yogi SundaravadanamOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Robert LubenDepartment of Public Health and Primary Care, Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Shabina HayatDepartment of Public Health and Primary Care, Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Ting Ting WangPrincess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.
Zhen ZhaoPrincess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.
Iulia CirlanPrincess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.
Trevor J PughPrincess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.
David SoaveOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Karen NgOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Calli LatimerWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Claire HardyWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Keiran RaineWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
David JonesWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Diana HoultMRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
Abigail BrittenMRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
John D McPhersonOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Mattias JohanssonInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Faridah MbabaaliOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Jenna EaglesOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Jessica K MillerOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Danielle PasternackOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Lee TimmsOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Paul KrzyzanowskiOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Philip AwadallaOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Rui CostaEuropean Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Wellcome Genome Campus, Hinxton, UK.
Eran SegalDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel.
Scott V BratmanPrincess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.
Philip BeerWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Sam BehjatiWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Inigo MartincorenaWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Jean C Y WangPrincess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.
Kristian M BowlesDepartment of Molecular Haematology, Norwich Medical School, The University of East Anglia, Norwich, UK.
J Ramón QuirósPublic Health Directorate, Asturias, Spain.
Anna KarakatsaniHellenic Health Foundation, Athens, Greece.
Carlo La VecchiaHellenic Health Foundation, Athens, Greece.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece.
Elena Salamanca-FernándezEscuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
José M HuertaCIBER Epidemiology and Public Health CIBERESP, Madrid, Spain.
Aurelio BarricarteCIBER Epidemiology and Public Health CIBERESP, Madrid, Spain.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Rosario TuminoCancer Registry and Histopathology Department, Civic-M. P. Arezzo Hospital, Azienda Sanitaria Provinciale, Ragusa, Italy.
Giovanna MasalaCancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Florence, Italy.
Heiner BoeingDepartment of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbrücke, Germany.
Salvatore PanicoDipartimento Di Medicina Clinica E Chirurgia, Federico II University, Naples, Italy.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Alwin KrämerClinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Sabina SieriEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Elio RiboliDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Paolo VineisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Matthieu FollInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
James McKayInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Silvia PolidoroItalian Institute for Genomic Medicine, Torino, Italy.
Núria SalaUnit of Nutrition and Cancer, Cancer Epidemiology Research Program and Translational Research Laboratory, Catalan Institute of Oncology, ICO-IDIBELL, Barcelona, Spain.
Kay-Tee KhawUniversity of Cambridge, Cambridge, UK.
Roel VermeulenDivision of Environmental Epidemiology and Veterinary Public Health, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
Peter J CampbellWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Elli PapaemmanuilWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Mark D MindenPrincess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada.
Amos TanayDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel.
Ran D BalicerClalit Research Institute, Tel Aviv, Israel.
Nicholas J WarehamMRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
Moritz GerstungWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK. moritz.gerstung@ebi.ac.uk.
John E DickPrincess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada. John.Dick@uhnresearch.ca.
Paul BrennanInternational Agency for Research on Cancer, World Health Organization, Lyon, France. BrennanP@iarc.fr.
George S VassiliouWellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK. gsv20@sanger.ac.uk.
Liran I ShlushPrincess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario, Canada. liranshlush3@gmail.com.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MCancer Research UK 14136Cancer Research UK 16491Cancer Research UK 21777Cancer Research UK 23015Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MC_PC_12009Medical Research Council MC_UU_12015/1Medical Research Council MR/N003284/1NCI NIH HHS P30 CA008748Wellcome TrustWorld Health Organization 001
Abstract
The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds 90% when diagnosed after age 65. Most cases arise without any detectable early symptoms and patients usually present with the acute complications of bone marrow failure
Indexed as
Genetic Predisposition to DiseaseHealthMutationAdultAgedAge FactorsDisease ProgressionElectronic Health RecordsFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedModels, GeneticMutagenesisPrevalence
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.